Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.
Status:
Completed
Trial end date:
2022-07-10
Target enrollment:
Participant gender:
Summary
Psoriasis is one of the most common immune-mediated inflammatory disorders characterized by a
chronic course. It affects approximately 2-3% of the world's population Psoriasis may be
provoked by environmental factors in patients with genetic predispositions. Psoriasis is
phenotypically characterized by thickened, red, scaly plaques and systemic inflammation, it
is also associated with multiple comorbidities, such as cardiovascular disease, stroke,
hypertension, metabolic diseases, chronic kidney disease, and joint destruction. Psoriasis is
pathogenically driven by proinflammatory cytokines and mediated by T and dendritic cells.
Inflammatory myeloid dendritic cells release interleukin (IL) 23 and IL-12 to activate
IL-17-producing T cells, Th1 cells, and Th22 cells to produce psoriatic cytokines like IL-17,
interferon (IFN) γ, TNF, and IL-22. These cytokines mediate the effects on keratinocytes.
Secukinumab is a recombinant human monoclonal antibody that specifically binds to a
proinflammatory cytokine released by T-helper-17 (Th17) cells, IL-17A. It blocks its binding
with IL-17R and the expression of cytokines. This blockade normalizes the inflammatory
processes and combats epidermal hyperproliferation, T-cell infiltration, and exaggerated
expression of pathogenic genes.